Abstract

Methods for making trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ9-tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-Δ9-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ9-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(−)-Δ9-tetrahydrocannabinol based on the total amount of trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(−)-Δ9-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.


Claims
Download PDF
Document Preview
Document History
  • Publication: Aug 29, 2017
  • Application: Mar 4, 2016
    US US 201615061780 A
  • Priority: Mar 4, 2016
    US US 201615061780 A
  • Priority: Jan 13, 2015
    US US 201514596034 A
  • Priority: Feb 22, 2013
    US US 201313774955 A
  • Priority: Aug 12, 2009
    US US 79141509 A
  • Priority: Nov 18, 2005
    EP EP 2005012378 W
  • Priority: Nov 22, 2004
    US US 63055604 P

Sign in to the Lens